Q1 2026 Bio/Pharma Private Funding Remains Difficult

Q1 2026 private biotech funding remains low and did not match the January-driven peak seen in early 2025, but overall capital deployment remained broadly comparable. Unlike Q1 2025’s front-loaded start, funding in Q1 2026 was more evenly distributed across the quarter, pointing to a more stable, though still selective, investment environment.

In total, private companies raised approximately $11.1B across 213 funding events in Q1 2026, compared to ~$12.0B across 301 events in Q1 2025 and ~$8.2B across 303 events in Q1 2024. While capital levels remained elevated versus 2024, a sharp decline in deal volume highlights continued investor selectivity. Early-stage funding also declined year-over-year, while grant activity increased to 44 events (~21% of total), underscoring the growing importance of non-dilutive capital.

---

Private Funding Activity

Private funding activity remained muted in Q1 2026, with 213 total events, down from ~300 deals in both Q1 2024 and Q1 2025 (Table 1 & Fig. 1).

• January led the quarter with 100 deals, followed by a sharp drop in February (54) and March (59)

• The decline in deal volume reflects continued selectivity in capital deployment

• Grant activity remained elevated, accounting for ~21% of total events, higher than prior years

Overall, the data suggests that while investors are still active, fewer companies are securing funding, particularly outside of high-conviction opportunities.

Table 1. Q1 Private Bio/Pharma Funding Snapshot (2024–2026)

	Q1 2024	Q1 2025	Q1 2026
Total Funding	~$8.16B	~$11.96B	~$11.08B
Total Events	303	301	213
Grants	41	36	44
Early-Stage Funding	~$2.86B	~$3.38B	~$2.27B
Early-Stage Events	119	117	73

Fig 1. Monthly funding events by Private Companies (2024 - 2026 Q1)

---

Total Private Funding Amounts

Despite lower deal volume, capital deployment remained relatively stable (Fig. 2).

• Q1 2026 funding totaled ~$11.1B, only slightly below Q1 2025 (~$12.0B) and well above Q1 2024 (~$8.2B)

Unlike 2025, where funding was heavily concentrated in January ($6.3B), 2026 showed a more balanced distribution. This shift suggests a less event-driven funding environment, with capital deployed more consistently across the quarter.

Fig. 2. Monthly funding amounts by Private Companies (2024 - 2026 Q1)

---

Early-Stage Funding

Early-stage funding remained under pressure in Q1 2026, both in terms of amounts and deal count (Fig. 3).

• Early-stage funding totaled ~$2.27B across 73 deals, down from ~$3.38B across 117 deals in Q1 2025

• January remained the strongest month (~$1.25B), followed by a sharp decline in February and partial recovery in March

While early-stage investment has not fully rebounded, continued deal flow indicates sustained investor interest, albeit with increased selectivity and smaller round sizes.

Fig. 3. Private early-stage funding activities: Number of deals & total amounts per month (2024 - 2026 Q1)

---

Public Market Sentiment

Public biotech markets showed mixed but stable performance in Q1 2026, following the strong recovery observed in the second half of 2025.

The XBI index opened the quarter at 121.52 on January 2 and closed at 127.73 on March 31, representing a ~5.1% increase. While the index experienced some volatility and softened during March, it remained well above mid-2025 levels (~77–83 range), when sentiment in small- and mid-cap biotech was significantly weaker.

The IBB index moved from 169.00 at the start of January to 168.85 at the end of March, reflecting a ~0.1% decline over the quarter. After a strong recovery through late 2025 (~120 in April 2025 to ~170 by year-end), the index showed signs of consolidation in Q1 2026, particularly in March.

Overall, public markets in Q1 2026 appear to be consolidating after the gains seen in late 2025, rather than entering a new upward phase. This stable but non-accelerating backdrop aligns with the continued selectivity observed in private funding activity, particularly at the early stage.

---

Concluding Remarks

Q1 2026 reflects a more balanced but still selective funding environment. While total capital raised remained broadly in line with prior years, deal volume and early-stage activity continued to decline. At the same time, stable public markets and elevated grant funding suggest that the foundation for a broader recovery remains in place, even if a full rebound has yet to materialize.

Data Source: BiopharmIQ

Explore BiopharmIQ Funding Activity Dataset!

Article History:

04/20/26 MD, RF, EJV

Not legal, investing, or tax advice.